Charles River Laboratories International, Inc.
CRL
$178.14
-$0.80-0.45%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.28M | -67.04M | -19.66M | 22.20M | 423.78M |
| Total Depreciation and Amortization | 346.74M | 420.77M | 351.85M | 352.34M | 340.15M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 520.11M | 392.18M | 425.15M | 390.36M | -18.23M |
| Change in Net Operating Assets | -35.09M | 41.55M | 19.05M | -30.33M | 50.46M |
| Cash from Operations | 749.49M | 787.45M | 776.39M | 734.58M | 796.16M |
| Capital Expenditure | -205.82M | -208.96M | -213.15M | -232.97M | -235.67M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | -5.48M | -5.48M | -150.10M |
| Divestitures | 17.44M | 17.44M | 17.44M | -- | -- |
| Other Investing Activities | -4.24M | 11.27M | -3.59M | -6.64M | -21.58M |
| Cash from Investing | -192.62M | -180.25M | -204.77M | -245.09M | -407.35M |
| Total Debt Issued | 1.18B | 1.30B | 1.20B | 1.08B | 1.42B |
| Total Debt Repaid | -1.32B | -1.39B | -1.35B | -1.49B | -1.64B |
| Issuance of Common Stock | 771.00K | 1.55M | 2.37M | 23.88M | 29.05M |
| Repurchase of Common Stock | -360.70M | -461.39M | -462.96M | -119.18M | -119.19M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -58.19M | -65.43M | -60.37M | -43.44M | -43.68M |
| Cash from Financing | -560.74M | -615.66M | -674.60M | -550.93M | -351.48M |
| Foreign Exchange rate Adjustments | 1.45M | 12.19M | -3.82M | -17.47M | 8.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.42M | 3.74M | -106.81M | -78.91M | 46.02M |